Literature DB >> 1849806

Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.

N Ling1, T Hansel, P Richardson, B Brown.   

Abstract

A soluble form of complement receptor 2 (sCR2) is found in normal human serum. Amounts present are about 30-90 ng/ml, which is of the same order as reported for soluble CR1. Although B cells express surface CR2 and are the main peripheral blood source of sCR2 they do not appear to be the major tissue source of serum sCR2. Serum levels of sCR2 of patients with hypogammaglobulinaemia were not significantly different from those of normal individuals even in the case of two brothers with Bruton's X-linked agammaglobulinaemia (XLA) lacking (CD19+) B cells. On gel filtration through Sephacryl S-300 the sCR2 from XLA serum behaved exactly like sCR2 from normal serum or sCR2 affinity purified from cell supernates of a B lymphoblastoid line or from the T-ALL line MOLT-4. In all cases a single peak appeared at the same point in the chromatogram. Possible alternative sources of serum sCR2 are follicular dendritic cells (FDC) which are known to express CR2 strongly and T6+ lymphocytes within the thymus. Peripheral T cells from adults have not been reported to express CR2. However, investigation showed that cells from the Bruton's XLA cases produced small amounts of sCR2 in culture and although no CD21 was detected on the surface of the mononuclear cells by flow cytometry, the more sensitive direct antibody rosette test readily detected CD21. Further studies showed that non-B cells from control samples of cord blood or blood of young children also weakly expressed CD21.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849806      PMCID: PMC1535368          DOI: 10.1111/j.1365-2249.1991.tb08117.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

Review 1.  Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).

Authors:  J M Ahearn; D T Fearon
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Epstein-Barr virus/complement receptor and epithelial cells.

Authors:  G Niedobitek; H Herbst; H Stein
Journal:  Lancet       Date:  1989-07-08       Impact factor: 79.321

3.  Structure-function relationships of the complement components.

Authors:  K B Reid; A J Day
Journal:  Immunol Today       Date:  1989-06

4.  Use of antibody-coated red cells for the sensitive detection of antigen and in rosette tests for cells bearing surface immunoglobulins.

Authors:  N R Ling; S Bishop
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

Review 5.  Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment.

Authors:  N R Cooper; M D Moore; G R Nemerow
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

6.  Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies.

Authors:  C D Tsoukas; J D Lambris
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

7.  A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues.

Authors:  N R Ling; D Hardie; J Lowe; G D Johnson; M Khan; I C MacLennan
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

8.  Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

Authors:  M Reynes; J P Aubert; J H Cohen; J Audouin; V Tricottet; J Diebold; M D Kazatchkine
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  Autoantibodies against gp140, the Epstein-Barr virus and C3d receptor in sera from rheumatoid arthritis patients.

Authors:  M Barel; A Kahan; C Charriaut-Marlangue; A Kahan; R Frade
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

10.  Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.

Authors:  C A Lowell; L B Klickstein; R H Carter; J A Mitchell; D T Fearon; J M Ahearn
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  10 in total

1.  Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes.

Authors:  H Illges; M Braun; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

3.  Origin and properties of soluble CD21 (CR2) in human blood.

Authors:  N R Ling; D L Hardie; G D Johnson; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

4.  Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL)

Authors:  N R Ling; F K Stevenson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

5.  Pitfalls in the measurement of soluble forms of cell surface receptors.

Authors:  N R Ling
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Authors:  Hui Zhi Low; Dorothee Hilbrans; Ingo G H Schmidt-Wolf; Harald Illges
Journal:  Int J Hematol       Date:  2012-08-17       Impact factor: 2.490

7.  Determination of soluble CD21 as a parameter of B cell activation.

Authors:  H P Huemer; C Larcher; W M Prodinger; A L Petzer; M Mitterer; N Falser
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

8.  Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies.

Authors:  Anjana Singh; Miri Blank; Yehuda Shoenfeld; Harald Illges
Journal:  Rheumatol Int       Date:  2008-01-03       Impact factor: 2.631

9.  Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.

Authors:  Madhan Masilamani; Narendiran Rajasekaran; Anjana Singh; Hui-Zhi Low; Kerstin Albus; Swantje Anders; Frank Behne; Peter Eiermann; Katharina König; Clarissa Mindnich; Teodora Ribarska; Harald Illges
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

10.  B-cell activity in children with malaria.

Authors:  Jackson C Korir; Japhet K Magambo; Joseph K Mwatha; John N Waitumbi
Journal:  Malar J       Date:  2012-03-09       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.